Literature DB >> 17387751

Telomerase activity, hTERT expression, and phosphorylation are downregulated in CD4(+) T lymphocytes infected with human immunodeficiency virus type 1 (HIV-1).

Ornella Franzese1, Riccardo Adamo, Michela Pollicita, Alessandro Comandini, Anastasia Laudisi, Carlo Federico Perno, Stefano Aquaro, Enzo Bonmassar.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) infection is characterized by a progressive decrease of CD4(+) T cells accompanied by other immune dysfunctions. Telomerase is transiently activated in lymphocytes during activation and is able to compensate for the progressive telomeric loss that occurs at each cell division, contributing to ensure the telomere length necessary for multiple proliferative events. The effect of HIV-1 infection on telomerase activity and on the expression of some of the factors involved in its regulation in CD4(+) T cells was investigated. Telomerase was found to be downregulated in both nuclear and cytoplasmic compartments, together with an impairment of human telomerase reverse transcriptase (hTERT) expression and of the cell machinery involved in hTERT phosporylation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17387751     DOI: 10.1002/jmv.20855

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  20 in total

1.  HIV-1 Vpr protein inhibits telomerase activity via the EDD-DDB1-VPRBP E3 ligase complex.

Authors:  Xin Wang; Shailbala Singh; Hae-Yun Jung; Guojun Yang; Sohee Jun; K Jagannadha Sastry; Jae-Il Park
Journal:  J Biol Chem       Date:  2013-04-23       Impact factor: 5.157

2.  CD4+ memory T cells infected with latent HIV-1 are susceptible to drugs targeting telomeres.

Authors:  Dorota Piekna-Przybylska; Sanjay B Maggirwar
Journal:  Cell Cycle       Date:  2018-09-20       Impact factor: 4.534

Review 3.  Aging and HIV/AIDS: pathogenetic role of therapeutic side effects.

Authors:  Rebecca A Torres; William Lewis
Journal:  Lab Invest       Date:  2013-12-16       Impact factor: 5.662

4.  HIV-1 induces telomerase activity in monocyte-derived macrophages, possibly safeguarding one of its reservoirs.

Authors:  Rita Reynoso; Matthias Wieser; Diego Ojeda; Maximilian Bönisch; Harald Kühnel; Federico Bolcic; Heribert Quendler; Johannes Grillari; Regina Grillari-Voglauer; Jorge Quarleri
Journal:  J Virol       Date:  2012-07-11       Impact factor: 5.103

5.  Deficiency in DNA damage response, a new characteristic of cells infected with latent HIV-1.

Authors:  Dorota Piekna-Przybylska; Gaurav Sharma; Sanjay B Maggirwar; Robert A Bambara
Journal:  Cell Cycle       Date:  2017-04-07       Impact factor: 4.534

Review 6.  Telomerase and primary T cells: biology and immortalization for adoptive immunotherapy.

Authors:  Eugene V Barsov
Journal:  Immunotherapy       Date:  2011-03       Impact factor: 4.196

Review 7.  CD4(+) T-cell depletion in HIV infection: mechanisms of immunological failure.

Authors:  Afam A Okoye; Louis J Picker
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

8.  Interferon alpha on expression of hTERT mRNA in peripheral blood mononuclear cells of patients with chronic hepatitis B.

Authors:  Chuan-wu Zhu; Ming Chen; Xiang-rong Luo; Hai-yan Wang; Li-hua Wang; Jian-hong Wu; Ming Li; Xue-hua Zhang; Wei Zhu; Jian-zhong Ye; Feng Qian
Journal:  Clin Dev Immunol       Date:  2011-05-15

Review 9.  Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions.

Authors:  Julie C Gaardbo; Hans J Hartling; Jan Gerstoft; Susanne D Nielsen
Journal:  Clin Dev Immunol       Date:  2012-03-14

10.  Apoptosis and telomeres shortening related to HIV-1 induced oxidative stress in an astrocytoma cell line.

Authors:  Michela Pollicita; Carolina Muscoli; Antonella Sgura; Alberto Biasin; Teresa Granato; Laura Masuelli; Vincenzo Mollace; Caterina Tanzarella; Claudio Del Duca; Paola Rodinò; Carlo Federico Perno; Stefano Aquaro
Journal:  BMC Neurosci       Date:  2009-05-22       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.